Pharvaris NV (PHVS)
18.35
-1.19
(-6.09%)
USD |
NASDAQ |
Jun 26, 12:29
Pharvaris Cash from Investing (Quarterly): -0.0334M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.0334M |
| December 31, 2023 | -0.0303M |
| September 30, 2023 | -0.0081M |
| June 30, 2023 | -0.0386M |
| March 31, 2023 | -0.0204M |
| December 31, 2022 | -0.0297M |
| September 30, 2022 | -0.0484M |
| June 30, 2022 | -0.0234M |
| March 31, 2022 | -0.0296M |
| Date | Value |
|---|---|
| December 31, 2021 | -0.0813M |
| September 30, 2021 | -0.0321M |
| June 30, 2021 | -0.0283M |
| March 31, 2021 | -0.0121M |
| December 31, 2020 | -0.0074M |
| September 30, 2020 | -0.0214M |
| June 30, 2020 | -0.0045M |
| March 31, 2020 | -0.0158M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-0.0813M
Minimum
Dec 2021
-0.0045M
Maximum
Jun 2020
-0.0273M
Average
-0.0283M
Median
Jun 2021
Cash from Investing (Quarterly) Benchmarks
| uniQure NV | 63.98M |
| ProQR Therapeutics NV | -19.26M |
| Merus NV | -12.08M |
| argenx SE | -- |
| Pharming Group | 0.664M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -26.32M |
| Cash from Financing (Quarterly) | 0.8636M |
| Free Cash Flow | -100.10M |
| Free Cash Flow Per Share (Quarterly) | -0.4897 |
| Free Cash Flow Yield | -12.14% |